B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

The past decade has witnessed significant advances in the systemic treatment of advanced
hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies …

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …

Immunotherapeutic efficacy of tumors based on immune checkpoint blockade (ICB) therapy
is frequently limited by an immunosuppressive tumor microenvironment and cross-reactivity …

Although advances in spatial transcriptomics (ST) enlarge to unveil spatial landscape of
tissues, it remains challenging to delineate pathology-relevant and cellular localizations …

Background Glioblastoma (GBM) is the most prominent and aggressive primary brain tumor
in adults. Anoikis is a specific form of programmed cell death that plays a key role in tumor …

Immunotherapy holds great promise for the treatment of aggressive and metastatic cancers;
however, currently available immunotherapeutics, such as immune checkpoint blockade …

Abstract Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a
crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving …

Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs)
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …

Emerging evidence supports that the efficacy of immune checkpoint blockade (ICB) therapy
is associated with the host's gut microbiota, as prior antibiotic intake often leads to poor …